A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined ...

Based in the Angolan capital of Luanda, on Africa’s southwest coast, FoodCare is a dried food manufacturer that processes and ...

The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Cassava Sciences, Inc.’s SAVA share price has dipped by 20.00%, which has investors questioning if this is right time to buy.

Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

After Cassava Sciences (SAVA) announced that top-line results from its ReFocus-ALZ Phase 3 trial with simufilam in patients with ...

Training hubs in Johannesburg and Cape Town will equip women and youth with the skills they need to thrive in the renewable ...